# Hyperfine, Inc.: financial statements, quarterly

HYPR · Nasdaq · CIK 1833769 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hypr.md) · [Financials](/companies/hypr/financials.md) · [Filings](/companies/hypr/filings.md) · [Insiders](/companies/hypr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hypr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.3](/filings/0000950170-24-125624.md) | [2.7 d](/filings/0000950170-25-040281.md) | [3.3](/filings/0000950170-25-070402.md) | [3.6](/filings/0000950170-25-108047.md) | [3.6](/filings/0001193125-25-280212.md) | [2.3 d](/filings/0001193125-26-114044.md) | [2.1](/filings/0001193125-26-219428.md) | [2.7](/filings/0001193125-26-338015.md) | [3.4](/filings/0001193125-25-280212.md) | [5.3 d](/filings/0001193125-26-114044.md) | [3.9](/filings/0001193125-26-219428.md) | [3.9](/filings/0001193125-26-338015.md) |
| Cost of revenue | $m | [1.2](/filings/0000950170-24-125624.md) | [1.7 d](/filings/0000950170-25-040281.md) | [1.9](/filings/0000950170-25-070402.md) | [1.8](/filings/0000950170-25-108047.md) | [1.7](/filings/0001193125-25-280212.md) | [1.5 d](/filings/0001193125-26-114044.md) | [1.3](/filings/0001193125-26-219428.md) | [1.4](/filings/0001193125-26-338015.md) | [1.6](/filings/0001193125-25-280212.md) | [2.6 d](/filings/0001193125-26-114044.md) | [1.9](/filings/0001193125-26-219428.md) | [1.9](/filings/0001193125-26-338015.md) |
| Gross profit | $m | [1.1](/filings/0000950170-24-125624.md) | [1.0 d](/filings/0000950170-25-040281.md) | [1.4](/filings/0000950170-25-070402.md) | [1.8](/filings/0000950170-25-108047.md) | [1.9](/filings/0001193125-25-280212.md) | [0.8 d](/filings/0001193125-26-114044.md) | [0.9](/filings/0001193125-26-219428.md) | [1.3](/filings/0001193125-26-338015.md) | [1.8](/filings/0001193125-25-280212.md) | [2.7 d](/filings/0001193125-26-114044.md) | [2.0](/filings/0001193125-26-219428.md) | [2.0](/filings/0001193125-26-338015.md) |
| Research and development | $m | [5.7](/filings/0000950170-24-125624.md) | [6.0 d](/filings/0000950170-25-040281.md) | [5.6](/filings/0000950170-25-070402.md) | [6.0](/filings/0000950170-25-108047.md) | [5.9](/filings/0001193125-25-280212.md) | [5.1 d](/filings/0001193125-26-114044.md) | [5.0](/filings/0001193125-26-219428.md) | [4.5](/filings/0001193125-26-338015.md) | [4.0](/filings/0001193125-25-280212.md) | [3.8 d](/filings/0001193125-26-114044.md) | [3.8](/filings/0001193125-26-219428.md) | [3.9](/filings/0001193125-26-338015.md) |
| Operating income | $m | [(11.8)](/filings/0000950170-24-125624.md) | [(11.6) d](/filings/0000950170-25-040281.md) | [(10.7)](/filings/0000950170-25-070402.md) | [(10.8)](/filings/0000950170-25-108047.md) | [(11.0)](/filings/0001193125-25-280212.md) | [(10.8) d](/filings/0001193125-26-114044.md) | [(10.9)](/filings/0001193125-26-219428.md) | [(9.6)](/filings/0001193125-26-338015.md) | [(8.9)](/filings/0001193125-25-280212.md) | [(7.7) d](/filings/0001193125-26-114044.md) | [(8.6)](/filings/0001193125-26-219428.md) | [(8.5)](/filings/0001193125-26-338015.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-219428.md) | [0.0](/filings/0001193125-26-338015.md) | not reported | not reported | [0.1](/filings/0001193125-26-219428.md) | [0.5](/filings/0001193125-26-338015.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-125624.md) | [0.0 d](/filings/0000950170-25-040281.md) | [0.0](/filings/0000950170-25-070402.md) | [0.0](/filings/0000950170-25-108047.md) | [0.0](/filings/0001193125-25-280212.md) | [0.0 d](/filings/0001193125-26-114044.md) | [0.0](/filings/0001193125-26-219428.md) | [0.0](/filings/0001193125-26-338015.md) | [0.0](/filings/0001193125-25-280212.md) | [0.0 d](/filings/0001193125-26-114044.md) | [0.0](/filings/0001193125-26-219428.md) | [0.0](/filings/0001193125-26-338015.md) |
| Net income | $m | [(10.8)](/filings/0000950170-24-125624.md) | [(10.7) d](/filings/0000950170-25-040281.md) | [(9.8)](/filings/0001193125-25-280212.md) | [(10.2)](/filings/0001193125-25-280212.md) | [(10.3)](/filings/0001193125-25-280212.md) | [(10.4) d](/filings/0001193125-26-114044.md) | [(9.4)](/filings/0001193125-26-338015.md) | [(9.2)](/filings/0001193125-26-338015.md) | [(11.0)](/filings/0001193125-25-280212.md) | [(5.9) d](/filings/0001193125-26-114044.md) | [(8.6)](/filings/0001193125-26-338015.md) | [(9.3)](/filings/0001193125-26-338015.md) |
| Diluted EPS | $ per share | [(0.15)](/filings/0000950170-24-125624.md) | not reported | [(0.14)](/filings/0000950170-25-070402.md) | [(0.14)](/filings/0000950170-25-108047.md) | [(0.14)](/filings/0001193125-25-280212.md) | not reported | [(0.12)](/filings/0001193125-26-219428.md) | [(0.12)](/filings/0001193125-26-338015.md) | [(0.14)](/filings/0001193125-25-280212.md) | not reported | [(0.09)](/filings/0001193125-26-219428.md) | [(0.09)](/filings/0001193125-26-338015.md) |
| Basic EPS | $ per share | [(0.15)](/filings/0000950170-24-125624.md) | not reported | [(0.14)](/filings/0000950170-25-070402.md) | [(0.14)](/filings/0000950170-25-108047.md) | [(0.14)](/filings/0001193125-25-280212.md) | not reported | [(0.12)](/filings/0001193125-26-219428.md) | [(0.12)](/filings/0001193125-26-338015.md) | [(0.14)](/filings/0001193125-25-280212.md) | not reported | [(0.09)](/filings/0001193125-26-219428.md) | [(0.09)](/filings/0001193125-26-338015.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [85.4](/filings/0000950170-24-125624.md) | [75.2](/filings/0000950170-25-040281.md) | [63.2](/filings/0000950170-25-070402.md) | [53.8](/filings/0000950170-25-108047.md) | [45.8](/filings/0001193125-25-280212.md) | [37.6](/filings/0001193125-26-114044.md) | [33.1](/filings/0001193125-26-219428.md) | [25.4](/filings/0001193125-26-338015.md) | [21.6](/filings/0001193125-25-280212.md) | [35.1](/filings/0001193125-26-338015.md) | [40.8](/filings/0001193125-26-219428.md) | [43.5](/filings/0001193125-26-338015.md) |
| Current assets | $m | [98.2](/filings/0000950170-23-062066.md) | [88.9](/filings/0000950170-25-040281.md) | [79.7](/filings/0000950170-24-059482.md) | [71.0](/filings/0000950170-24-094720.md) | [64.1](/filings/0000950170-24-125624.md) | [53.7](/filings/0001193125-26-114044.md) | [48.4](/filings/0000950170-25-070402.md) | [40.1](/filings/0000950170-25-108047.md) | [36.9](/filings/0001193125-25-280212.md) | [50.9](/filings/0001193125-26-338015.md) | [56.0](/filings/0001193125-26-219428.md) | [59.2](/filings/0001193125-26-338015.md) |
| Total assets | $m | [103](/filings/0000950170-23-062066.md) | [94.2](/filings/0000950170-25-040281.md) | [85.4](/filings/0000950170-24-059482.md) | [76.6](/filings/0000950170-24-094720.md) | [69.4](/filings/0000950170-24-125624.md) | [58.9](/filings/0001193125-26-114044.md) | [53.4](/filings/0000950170-25-070402.md) | [45.2](/filings/0000950170-25-108047.md) | [41.5](/filings/0001193125-25-280212.md) | [55.3](/filings/0001193125-26-338015.md) | [60.3](/filings/0001193125-26-219428.md) | [63.0](/filings/0001193125-26-338015.md) |
| Current liabilities | $m | [8.2](/filings/0000950170-23-062066.md) | [8.8](/filings/0000950170-25-040281.md) | [8.8](/filings/0000950170-24-059482.md) | [8.8](/filings/0000950170-24-094720.md) | [10.0](/filings/0000950170-24-125624.md) | [8.7](/filings/0001193125-26-114044.md) | [8.0](/filings/0000950170-25-070402.md) | [8.0](/filings/0000950170-25-108047.md) | [10.2](/filings/0001193125-25-280212.md) | [11.7](/filings/0001193125-26-338015.md) | [10.2](/filings/0001193125-26-219428.md) | [9.6](/filings/0001193125-26-338015.md) |
| Total liabilities | $m | [9.3](/filings/0000950170-23-062066.md) | [9.8](/filings/0000950170-25-040281.md) | [9.8](/filings/0000950170-24-059482.md) | [9.8](/filings/0000950170-24-094720.md) | [11.1](/filings/0000950170-24-125624.md) | [9.9](/filings/0001193125-26-114044.md) | [10.3](/filings/0000950170-25-070402.md) | [10.1](/filings/0000950170-25-108047.md) | [14.6](/filings/0001193125-25-280212.md) | [14.3](/filings/0001193125-26-338015.md) | [26.0](/filings/0001193125-26-219428.md) | [26.2](/filings/0001193125-26-338015.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-338015.md) | [13.1](/filings/0001193125-26-219428.md) | [13.2](/filings/0001193125-26-338015.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-219428.md) | [0.0](/filings/0001193125-26-338015.md) |
| Shareholders' equity | $m | [93.8](/filings/0000950170-24-125624.md) | [84.4](/filings/0001193125-26-114044.md) | [75.6](/filings/0001193125-25-280212.md) | [66.8](/filings/0001193125-25-280212.md) | [58.3](/filings/0001193125-25-280212.md) | [49.0](/filings/0001193125-26-338015.md) | [43.1](/filings/0001193125-26-338015.md) | [35.1](/filings/0001193125-26-338015.md) | [26.9](/filings/0001193125-25-280212.md) | [41.0](/filings/0001193125-26-338015.md) | [34.4](/filings/0001193125-26-338015.md) | [36.8](/filings/0001193125-26-338015.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.7) d](/filings/0000950170-24-125624.md) | [(9.9) d](/filings/0000950170-25-040281.md) | [(12.5)](/filings/0000950170-25-070402.md) | [(9.4) d](/filings/0000950170-25-108047.md) | [(8.5) d](/filings/0001193125-25-280212.md) | [(8.4) d](/filings/0001193125-26-114044.md) | [(9.2)](/filings/0001193125-26-219428.md) | [(7.9) d](/filings/0001193125-26-338015.md) | [(5.6) d](/filings/0001193125-25-280212.md) | [(5.2) d](/filings/0001193125-26-114044.md) | [(9.0)](/filings/0001193125-26-219428.md) | [(7.3) d](/filings/0001193125-26-338015.md) |
| Capital expenditure | $m | [0.3 d](/filings/0000950170-24-125624.md) | [0.3 d](/filings/0000950170-25-040281.md) | [0.1](/filings/0000950170-25-070402.md) | [0.1 d](/filings/0000950170-25-108047.md) | [0.2 d](/filings/0001193125-25-280212.md) | [0.0 d](/filings/0001193125-26-114044.md) | [0.5](/filings/0001193125-26-219428.md) | [0.5 d](/filings/0001193125-26-338015.md) | [0.1 d](/filings/0001193125-25-280212.md) | [0.1 d](/filings/0001193125-26-114044.md) | [0.2](/filings/0001193125-26-219428.md) | [0.0 d](/filings/0001193125-26-338015.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [70.5](/filings/0000950170-23-062066.md) | [70.9](/filings/0000950170-24-059482.md) | [71.2](/filings/0000950170-24-094720.md) | [71.5](/filings/0000950170-24-125624.md) | [71.9](/filings/0000950170-25-070402.md) | [72.0](/filings/0000950170-25-108047.md) | [72.7](/filings/0001193125-25-280212.md) | [75.7](/filings/0001193125-26-219428.md) | [78.1](/filings/0001193125-26-338015.md) | [79.0](/filings/0001193125-25-280212.md) | [97.7](/filings/0001193125-26-219428.md) | [99.8](/filings/0001193125-26-338015.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.